trending Market Intelligence /marketintelligence/en/news-insights/trending/n-CbPlTmiheJ9hu1SQ396Q2 content esgSubNav
In This List

Bristol-Myers, Taris to evaluate Opdivo combo in bladder cancer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Bristol-Myers, Taris to evaluate Opdivo combo in bladder cancer

Bristol-Myers Squibb Co. and Taris BioMedical LLC will collaborate to evaluate Taris' TAR-200, in combination with Bristol-Myers' Opdivo, in patients with bladder cancer.

Under the collaboration, the combination will be evaluated in a phase 1b trial in patients with muscle invasive bladder cancer who are scheduled for radical cystectomy, or the removal of the entire bladder.

Bristol-Myers also made an equity investment in TARIS as part of the collaboration.